Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

NCT07626281 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Inclisiran Formulation

Interventions

DRUG: Inclisiran formulation containing PS80
DRUG: Currently marketed inclisiran formulation

Sponsor

Novartis Pharmaceuticals